Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
Background: Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis. Raloxifene is also indicated to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk...
| Publicado en: | BMC Women's Health Vol. 13; no. 1; pp. 15 - 16 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
BioMed Central
2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104271191&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104271191 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14726874 1CIP jtl: BMC Women's Health issn: 14726874 maglogo: N pubinfo: dt: 2013 vid: 13 iid: 1 pid: 24147 pub: BioMed Central artinfo: ui: 104271191 104271191 NLM23521803 2012083933 10.1186/1472-6874-13-15 NLM23521803 PMC3626542 104271191 ppf: 15 ppct: 1 formats: fmt: @attributes: type: P tig: atl: Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. aug: au: Foster, Shonda A Shi, Nianwen Curkendall, Suellen Stock, John Chu, Bong-Chul Burge, Russel Diakun, David R Krege, John H affil: Eli Lilly and Company, Indianapolis, IN, USA. fostersa@lilly.com sug: subj: Alendronate Administration and Dosage Diphosphonates Administration and Dosage Fractures Epidemiology Osteoporosis Complications Osteoporosis Drug Therapy Raloxifene Administration and Dosage Aged Bone Density Drug Effects Breast Neoplasms Epidemiology Comorbidity Female Human Middle Age Osteoporosis Epidemiology Prospective Studies Retrospective Design United States Women's Health Aged: 65+ years Middle Aged: 45-64 years Female ab: Background: Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis. Raloxifene is also indicated to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer. A definitive study comparing the fracture effectiveness and rate of breast cancer for raloxifene and alendronate has not been published. The purpose of this retrospective cohort study was to evaluate fracture and breast cancer rates among patients treated with raloxifene or alendronate.Methods: Females ≥45 years who initiated raloxifene or alendronate in 1998-2006 Truven Health Analytics MarketScan® Databases, had continuous enrollment 12 months prior to and at least 12 months after the index date, and had a treatment medication possession ratio ≥80% were included in this study. Rates of vertebral and nonvertebral fractures and breast cancer during 1, 3, 5, 6, 7, and 8 years of treatment with raloxifene or alendronate were evaluated. Fracture rates were adjusted for potential treatment bias using inverse probability of treatment weights. Multivariate hazard ratios were estimated for vertebral and nonvertebral fractures.Results: Raloxifene patients had statistically significantly lower rates of vertebral fractures in 1, 3, 5, and 7 years and for nonvertebral fractures in 1 and 5 years. There were no statistically significant differences in the adjusted fracture rates between raloxifene and alendronate cohorts, except in the 3-year nonvertebral fracture rates where raloxifene was higher. Multivariate hazard ratios of raloxifene versus alendronate cohorts were not significantly different for vertebral and nonvertebral fracture in 1, 3, 5, 6, 7, and 8 years. Unweighted and weighted breast cancer rates were lower among raloxifene recipients.Conclusions: Patients treated with alendronate and raloxifene had similar adjusted fracture rates in up to 8 years of adherent treatment, and raloxifene patients had lower breast cancer rates. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|